Skip to main content

Table 1 Costs estimated for a three-month period (one Markov model cycle) of each health state of the model, in Brazilian real (BRL) and percentage (%) by category in strategy 1 (XELOX)

From: Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

Category First-line treatment (XELOX) Second-line treatment (FOLFIRI) Supportive care Death
R$ % R$ % R$ % R$ %
Medications 6428.00 77.86 4327.80 33.33 0.00 0.00 0.00 0.00
Preparation (Pharmacy) 81.24 0.98 270.18 2.08 0.00 0.00 0.00 0.00
Administration (Nursing) 580.80 7.03 6700.74 51.61 0.00 0.00 0.00 0.00
Laboratory tests 265.48 3.22 409.08 3.15 265.48 5.28 0.00 0.00
Imaging tests 900.80 10.91 1276.20 9.83 0.00 0.00 0.00 0.00
Hospitalization 0.00 0.00 0.00 0.00 4767.03 94.72 0.00 0.00
Total 8256.32 100.00 12,984.00 100.00 5032.51 100.00 0.00 0.00
  1. Abbreviations: XELOX Xeloda® and oxaliplatin, FOLFIRI 5-fluorouracil, leucovorin and irinotecan